title: Primary brain CD30+ ALK1+ anaplastic large cell lymphoma ('ALKoma'): the first case with a combination of 'not common' variants.
abstract: BACKGROUND
  Primary central nervous system lymphomas (PCNSLs) are rare tumors, mostly represented by diffuse large B cells. PCNSLs with a T phenotype are less frequently reported; even rarer are anaplastic large cell lymphomas (ALCLs). PCNSL ALCLs are commonly represented, like their systemic counterpart, by a variably prevalent amount of large pleomorphic tumor cells ('hallmark cells'), and this feature enhances their recognition. Patient and methods We report the first case of primary brain CD30+ ALK-1+ ALCL with a T-cell phenotype, showing the combination of both the 'lymphohistiocytic' and the 'small cell' variants of the disease. A few elements consistent with 'hallmark cells' were recognizable. However, these cells were never prominent, increasing diagnostic difficulties. Immunohistochemistry results were critical for the correct interpretation. Our findings also differ from the majority of PCNSL ALCLs for the absence of tumor necrosis and the lack of prominent mitotic activity. The neuroimaging picture was not specific. A comparison with literature data concerning the clinical/instrumental features shows a very frequent meningeal involvement in PCNSL ALCLs, in contrast to the majority of PCNSLs.
  
  
  CONCLUSIONS
  The occurrence of such a rare form of ALCL may widen the spectrum of differential diagnoses in PCNSL and their recognition may allow a rapid diagnosis, thus encouraging adequate treatment, which should take into account the high rate of meningeal involvement observed in these cases.
authors.affiliation: Departments of Pathology, S Raffaele H Scientific Institute, Milan, Italy. ponzoni.maurilio@hsr.it
authors.forename: M
authors.initials: M
authors.lastname: Ponzoni
authors.forename: M R
authors.initials: MR
authors.lastname: Terreni
authors.forename: F
authors.initials: F
authors.lastname: Ciceri
authors.forename: A J M
authors.initials: AJ
authors.lastname: Ferreri
authors.forename: S
authors.initials: S
authors.lastname: Gerevini
authors.forename: N
authors.initials: N
authors.lastname: Anzalone
authors.forename: M
authors.initials: M
authors.lastname: Valle
authors.forename: S
authors.initials: S
authors.lastname: Pizzolito
authors.forename: G
authors.initials: G
authors.lastname: Arrigoni
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D001707:Biopsy, Needle; D001932:Brain Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000473:pathology*; D005500:Follow-Up Studies; D006801:Humans; D007121:Immunocompetence; D007150:Immunohistochemistry; D017730:Ki-1 Antigen / Q000032:analysis*; D017728:Lymphoma, Large-Cell, Anaplastic / Q000188:drug therapy / Q000276:immunology / Q000473:pathology*; D008279:Magnetic Resonance Imaging; D008297:Male; D009367:Neoplasm Staging; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D017730:Ki-1 Antigen